BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2589363)

  • 1. Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
    Abadie-Kemmerly S; Pankey GA
    Am J Med; 1989 Nov; 87(5A):213S-220S. PubMed ID: 2589363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
    Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
    Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
    Peacock JE; Pegram PS; Weber SF; Leone PA
    Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous ciprofloxacin in difficult-to-treat infections.
    Giamarellou H; Galanakis N
    Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime.
    Quintero-Perez NP; Andrade-Villaneuva JF; Leon-Garnica G; Bertin-Montano M; Rodriguez-Chagollan JJ; Rodriguez-Noriega E
    Am J Med; 1989 Nov; 87(5A):198S-201S. PubMed ID: 2686424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
    Villavicencio J; Asensio de Fernandez ME; Ramirez CA
    Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
    Sifuentes-Osornio J; MacĂ­as A; Amieva RI; Ramos A; Ruiz-Palacios GM
    Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ciprofloxacin therapy in severe infections.
    Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
    Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Levine DP; McNeil P; Lerner SA
    Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
    Neu HC; Davidson S; Briones F
    Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
    Brown AE; Smith G
    Am J Med; 1989 Nov; 87(5A):266S-268S. PubMed ID: 2589376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
    Davis C
    Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
    Parish LC; Asper R
    Am J Med; 1987 Apr; 82(4A):227-9. PubMed ID: 3555041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of intravenous ciprofloxacin. A review.
    Arcieri GM; Becker N; Esposito B; Griffith E; Heyd A; Neumann C; O'Brien B; Schacht P
    Am J Med; 1989 Nov; 87(5A):92S-97S. PubMed ID: 2686431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.